ACCOUNT

Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

PGe
NEWSLETTERS
PG STORE
ARCHIVES

CLASSIFIEDS

OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS

CONTACT US
ADVERTISING
CAREER OPPORTUNITIES

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Roivant Sciences

< Previous 1 2 3 Next >

Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

September 26, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant Announces Completion of Redemption of its Outstanding Warrants

September 11, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants

August 17, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update

August 14, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023

August 03, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant Announces Redemption of Outstanding Warrants

August 02, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease

July 27, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program

July 11, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update

June 28, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update

June 28, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023

June 26, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period

June 22, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis

June 21, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old

May 16, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old

March 15, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis

March 14, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs

March 14, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement

March 07, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant Sciences Announces Change to its Board of Directors

February 21, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update

February 13, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares

February 02, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant Sciences Announces Proposed Public Offering of Common Shares

February 01, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023

January 30, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker

January 04, 2023

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases

December 01, 2022

From Roivant Sciences

Via GlobeNewswire

Tickers PFE ROIV ROIVW

Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update

November 14, 2022

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC

November 10, 2022

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering

November 08, 2022

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant Sciences Announces Proposed Public Equity Offering

November 07, 2022

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences

October 18, 2022

From Roivant Sciences

Via GlobeNewswire

Tickers ROIV ROIVW

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.